HY 009 B2
Alternative Names: HY-009B2Latest Information Update: 04 Feb 2025
At a glance
- Originator Helperby Therapeutics
- Class Anti-infectives; Antibacterials; Urinary anti-infective agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Intra-abdominal infections; Urinary tract infections
Most Recent Events
- 03 Feb 2025 HY 009 B2 is still undergoing early research in Urinary tract infections, Intra-abdominal infections and Urinary tract infections (Complicated) in United Kingdom (PO) (Helperby Therapeutics pipeline, February 2025)
- 28 Jul 2024 No recent reports of development identified for research development in Intra-abdominal-infections in United Kingdom (PO)
- 28 Jul 2024 No recent reports of development identified for research development in Urinary-tract-infections in United Kingdom (PO)